High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis

Journal of Pathology

Volumn 206, Issue 3, 2005, Pages 328-336

  Riemersma, Sietske A ^a,f   Oudejans, Joost J ^b   Vonk, Marcel J ^a   Dreef, Enno J ^a   Prins, Frans A ^a   Jansen, Patty M ^a   Vermeer, Maarten H ^a   Blok, Paul ^d   Kibbelaar, Robbie E ^e   Muris, Jettie J F ^b   Schuuring, Ed M D ^c   Kluin, Philip M ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e Lab V Volksgezondheid in Friesland   (Netherlands)

^f Laboratorium Pathologie Oost Nederland   (Netherlands)

Author keywords

Central nervous system (CNS); Cytotoxic T lymphocytes (CTL); Human leucocyte antigens (HLA); Lymphoma; Testis

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BRAIN LYMPHOMA; CANCER LOCALIZATION; CANCER SURVIVAL; CELL GROWTH; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; LYMPHOMA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN LYMPHOMA; STATISTICAL ANALYSIS; STOMACH LYMPHOMA; T LYMPHOCYTE ACTIVATION; TESTIS CANCER; TISSUE SECTION;

ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; PHENOTYPE; SKIN NEOPLASMS; STOMACH NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TESTICULAR NEOPLASMS;

EID: 21344448199     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1783     Document Type: Article

References (56)

1. Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA 1989;86(1):282-286.
2. Sproul TW, Cheng PC, Dykstra ML, Pierce SK. A role for MHC class II antigen processing in B cell development. Int Rev Immunol 2000;19(2-3):139-155.
3. Chaperot L, Jacob MC, Molens JP, Manches O, Bensa JC, Plumas J. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas. Leuk Lymphoma 2000;38(3-4):247-263.
4. Guy K, Krajewski AS, Dewar AE. Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma. Br J Cancer 1986;53(2):161-173.
5. Amiot L, Onno M, Lamy T, et al. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 1998;100(4):655-663.
6. Spier CM, Grogan TM, Lippman SM, Slymen DJ, Rybski JA, Miller TP. The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. Am J Pathol 1988;133(1):118-126.
7. Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988;82(1):370-372.
8. Moller P, Lammler B, Herrmann B, Otto HF, Moldenhauer G, Momburg F. The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology 1986; 59(3):411-417.
9. Moller P, Herrmann B, Moldenhauer G, Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer 1987;40(1):32-39.
10. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162(1):243-253.
11. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96(10):3569-3577.
12. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994;76(6):977-987.
13. Muris JJ, Meijer CJ, Cillessen SA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18(3):589-596.
14. Isaacson PG. The revised European-American lymphoma (REAL) classification. Clin Oncol (R Coll Radiol) 1995; 7(6):347-348.
15. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14(7):2131-2138.
16. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995;86(7):2715-2723.
17. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2(2):113-125.
18. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997;89(4):1376-1382.
19. Bladergroen BA, Meijer CJ, ten Berge RL, et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002;99(1):232-237.
20. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338(8776):1175-1176.
21. Geelen FA, Vermeer MH, Meijer CJ, et al bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol 1998;16(6):2080-2085.
22. Ferguson TA, Green DR, Griffith TS. Cell death and immune privilege. Int Rev Immunol 2002;21(2-3):153-172.
23. Yakirevich E, Yanai O, Sova Y, et al. Cytotoxic phenotype of intra-epithelial lymphocytes in normal and cryptorchid human testicular excurrent ducts. Hum Reprod 2002;17(2):275-283.
24. Schurmans LR, den Boer AT, Diehl L, et al. Successful immunotherapy of an intraocular tumor in mice. Cancer Res 1999; 59(20):5250-5254.
25. Walker PR, Calzascia T, Schnuriger V, et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol 2000; 165(6):3128-3135.
26. Yamasaki T, Akiyama Y, Fukuda M, et al. Natural resistance against tumors grafted into the brain in association with histocompatibility-class-I-antigen expression. Int J Cancer 1996; 67(3):365-371.
27. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998;91(8):2875-2885.
28. Chaperot L, Manches O, Mi JQ, et al. Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas. Br J Haematol 2002; 119(2):425-431.
29. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63(11):2836-2843.
30. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000; 6(6):667-672.
31. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004;103(5):1869-1875.
32. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003;90:127-156.
33. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001;19(3):720-726.
34. Guidoboni M, Doglioni C, Laurino L, Boiocchi M, Dolcetti R. Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas: differences between high-grade and low-grade cases. Am J Pathol 1999;155(3):823-829.
35. Bashir R, Chamberlain M, Ruby E, Hochberg FH. T-cell infiltration of primary CNS lymphoma. Neurology 1996; 46(2):440-444.
36. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspase 9 ICE/Ced-3 proteases. Blood 1997;90(8):3118-3129.
37. Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998;92(9):3018-3024.
38. Takakuwa T, Dong Z, Takayama H, Matsuzuka F, Nagata S, Aozasa K. Frequent mutations of Fas gene in thyroid lymphoma. Cancer Res 2001;61(4):1382-1385.
39. Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91(10):4185-4189.
40. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152(3):1127-1133.
41. Williams NS, Engelhard VH. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 1996;156(1):153-159.
42. Lewinsohn DM, Bement TT, Xu J, et al. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol 1998; 160(5):2374-2379.
43. Yasukawa M, Yakushijin Y, Fujita S. Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus-specific CD4+ human cytotoxic T cell clones. Clin Immunol Immunopathol 1996; 78(1):70-76.
44. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 2000; 95(7):2352-2355.
45. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103(11):4251-4258.
46. Truman JP, Ericson ML, Choqueux-Seebold CJ, Charron DJ, Mooney NA. Lymphocyte programmed cell death is mediated via HLA class II DR. Int Immunol 1994;6(6):887-896.
47. Yoshino T, Cao L, Nishiuchi R, et al. Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. Eur J Immunol 1995; 25(8):2190-2194.
48. Truman JP, Choqueux C, Tschopp J, et al. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood 1997;89(6):1996-2007.
49. Vidovic D, Toral JI. Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody. Cancer Lett 1998; 128(2):127-135.
50. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002;8(8):801-807.
51. Stockmeyer B, Schiller M, Repp R, et al. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10: a humanized human leucocyte antigen DR antibody. Br J Haematol 2002;118(4):959-967.
52. Blancheteau V, Charron D, Mooney N. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum Immunol 2002;63(5):375-383.
53. Dechant M, Vidarsson G, Stockmeyer B, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002;100(13):4574-4580.
54. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002;35(1):38-48.
55. Jordanova ES, Philippo K, Giphart MJ, Schuuring E, Kluin PM. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 2003;55(4):203-209.
56. Montesinos-Rongen M, Kuppers R, Schluter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999;155(6):2077-2086.